REDUCTION OF LDL CHOLESTEROL BY PRAVASTATIN DOES NOT INFLUENCE PLATELET ACTIVATION IN PATIENTS WITH MILD HYPERCHOLESTEROLEMIA AT RISK OF CORONARY HEART-DISEASE

被引：17

作者：

BARROW, SE ^{[1
]}

STRATTON, PD ^{[1
]}

BENJAMIN, N ^{[1
]}

BRASSFIELD, T ^{[1
]}

RITTER, JM ^{[1
]}

机构：

[1] BRISTOL MYERS SQUIBB PHARMACEUT,CLIN RES DEPT,HOUNSLOW TW3 3JA,MIDDX,ENGLAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 32卷 / 01期

关键词：

THROMBOXANE A2; PLATELET ACTIVATION; PRAVASTATIN; LDL; HYPERCHOLESTEROLEMIA;

D O I：

10.1111/j.1365-2125.1991.tb05625.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effect of pravastatin on low density lipoprotein (LDL) cholesterol and platelet activation was studied in 16 patients with mild hypercholesterolaemia who had two or more additional cardiovascular risk factors. Patients were treated with either pravastatin (20-40 mg day-1) or placebo for 1 year. Plasma LDL and urinary excretion of 2,3-dinor-thromboxane B2 (an index of platelet activation in vivo) were determined at 0, 3, 6 and 12 months. There was a significant reduction in LDL at 6 and 12 months (2P < 0.05) but this was not associated with any significant change in thromboxane metabolite excretion.

引用

页码：127 / 129

页数：3

共 50 条

[1] EFFECT OF PRAVASTATIN IN THE PREVENTION OF CORONARY HEART-DISEASE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
ATHYROS, VG
PAPAGEORGIOU, AA
AVRAMIDIS, MJ
KARAYANNIS, AJ
ZAMBOULIS, CX
KONTOPOULOS, AG
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (08): : 914 - 924
[2] PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
SHEPHERD, J
COBBE, SM
FORD, I
ISLES, CG
LORIMER, AR
MACFARLANE, PW
MCKILLOP, JH
PACKARD, CJ
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20): : 1301 - 1307
[3] CUMULATIVE LDL CHOLESTEROL LEVEL AND OTHER RISK FACTORS INFLUENCE ON CORONARY HEART DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
Korneva, V.
Kuznetsova, T.
ATHEROSCLEROSIS, 2021, 331 : E177 - E177
[4] CHOLESTEROL LOWERING AND THE REDUCTION OF CORONARY HEART-DISEASE RISK
RIFKIND, BM
LENFANT, C
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20): : 2872 - 2873
[5] MARKERS OF PLATELET ACTIVATION IN CORONARY HEART-DISEASE PATIENTS
NURDEN, AT
MACCHI, L
BIHOUR, C
DURRIEU, C
BESSE, P
NURDEN, P
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1994, 24 : 42 - 45
[6] Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: The Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial
Shimizu, M
Koizumi, J
Miyamoto, S
Origasa, H
Mabuchi, H
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 99 (03) : 395 - 401
[7] CHOLESTEROL AND CORONARY HEART-DISEASE RISK IN ELDERLY PATIENTS
HARRIS, T
HAVLIK, R
ETTINGER, WH
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (17): : 1329 - 1329
[8] LDL-CHOLESTEROL AS A DETERMINANT OF CORONARY HEART-DISEASE
HUNNINGHAKE, D
CLINICAL THERAPEUTICS, 1990, 12 (05) : 370 - 375
[9] CHOLESTEROL AND CORONARY HEART-DISEASE - THE ATTRIBUTABLE RISK REDUCTION OF DIET AND DRUGS
MALENKA, DJ
BARON, JA
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (09) : 1981 - 1985
[10] DOES REDUCTION OF PLASMA-CHOLESTEROL NORMALIZE ENHANCED PLATELET ACTIVITY IN PATIENTS WITH CORONARY HEART-DISEASE AND HYPERCHOLESTEROLEMIA - RESULTS OF A 4 WEEK LOVASTATIN THERAPY ON BLOOD-PLATELET ACTIVITY AND MEMBRANES
SHALAEV, SV
SAFIULLINA, ZM
MEZETSKAYA, IA
ZURAVLEVA, TD
ZMUROV, VA
THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 924 - 924

← 1 2 3 4 5 →